全文获取类型
收费全文 | 5417篇 |
免费 | 321篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 123篇 |
妇产科学 | 59篇 |
基础医学 | 721篇 |
口腔科学 | 154篇 |
临床医学 | 494篇 |
内科学 | 1155篇 |
皮肤病学 | 48篇 |
神经病学 | 551篇 |
特种医学 | 240篇 |
外科学 | 647篇 |
综合类 | 10篇 |
一般理论 | 7篇 |
预防医学 | 554篇 |
眼科学 | 16篇 |
药学 | 527篇 |
中国医学 | 6篇 |
肿瘤学 | 428篇 |
出版年
2024年 | 6篇 |
2023年 | 26篇 |
2022年 | 35篇 |
2021年 | 77篇 |
2020年 | 63篇 |
2019年 | 98篇 |
2018年 | 97篇 |
2017年 | 92篇 |
2016年 | 97篇 |
2015年 | 115篇 |
2014年 | 192篇 |
2013年 | 247篇 |
2012年 | 421篇 |
2011年 | 455篇 |
2010年 | 265篇 |
2009年 | 231篇 |
2008年 | 408篇 |
2007年 | 462篇 |
2006年 | 381篇 |
2005年 | 408篇 |
2004年 | 345篇 |
2003年 | 327篇 |
2002年 | 290篇 |
2001年 | 63篇 |
2000年 | 36篇 |
1999年 | 55篇 |
1998年 | 78篇 |
1997年 | 64篇 |
1996年 | 51篇 |
1995年 | 41篇 |
1994年 | 37篇 |
1993年 | 50篇 |
1992年 | 15篇 |
1991年 | 17篇 |
1990年 | 23篇 |
1989年 | 10篇 |
1988年 | 9篇 |
1987年 | 7篇 |
1986年 | 9篇 |
1985年 | 6篇 |
1984年 | 10篇 |
1983年 | 7篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 5篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1966年 | 1篇 |
1964年 | 1篇 |
排序方式: 共有5756条查询结果,搜索用时 15 毫秒
61.
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. 总被引:1,自引:0,他引:1
Diana C J Spierings Elisabeth G E de Vries Wim Timens Harry J M Groen H Marike Boezen Steven de Jong 《Clinical cancer research》2003,9(9):3397-3405
PURPOSE: Several in vitro studies have shown that non-small cell lung cancer (NSCLC) cell lines are sensitive to apoptosis induction by the recombinant human (rh) tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death ligand, indicating that rhTRAIL might become an attractive molecule for treatment of NSCLCs. To investigate the therapeutic potential of rhTRAIL, the expression of TRAIL and its apoptosis-inducing receptors DR4 and DR5 was evaluated in tumors of stage III NSCLC patients. EXPERIMENTAL DESIGN: Before treatment, tumor biopsies from locally advanced NSCLC patients were obtained by bronchoscopy. DR4, DR5, and TRAIL expression were determined immunohistochemically in 87 tumors. Patients were randomized for treatment with 60 Gy radiotherapy with or without carboplatin as radiosensitizer. RESULTS: DR4, DR5, and TRAIL were expressed in 99%, 82%, and 91% of the tumors, respectively. Seventeen percent of the samples expressed only DR4 and no DR5. In NSCLCs with squamous cell differentiation, a typical staining pattern for DR4 and DR5 was observed. Cells from the basal layer were strongly positive, and the more mature cells were less positive or negative. An inverse staining pattern was observed for TRAIL. Poorly differentiated areas showed strong staining intensity for DR4, DR5, and TRAIL. DR5-positive staining was associated with increased risk of death (odds ratio, 5.76; 95% confidence interval, 1.04-31.93; P = 0.045). CONCLUSIONS: The majority of the locally irresectable stage III NSCLCs expressed at least one of the two death receptors for TRAIL. Therefore, these death receptors may provide a target for the use of rhTRAIL as a new adjunct in the treatment of stage III NSCLC. 相似文献
62.
Steinar Aamdal Uta Bruntsch Jean Kerger Jaap Verweij Wim Bokkel Huinink Jantien Wanders Ram Rastogi Hillary R. Franklin Stan B. Kaye 《Cancer chemotherapy and pharmacology》1997,40(5):439-443
The antitumor activity of zeniplatin, a third-generation, water-soluble platinum compound that has shown broad preclinical
antitumor activity and no significant nephrotoxicity in phase I trials, was tested in patients with advanced malignant melanoma
and advanced renal cancer. Patients who had not previously been treated, except with local limb perfusion and immunotherapy,
were given zeniplatin as bolus injections at 125 mg/m2 every 3 weeks. The main hematological toxicity was leukopenia (7/30 patients, WHO grade ≥ 3) and the main nonhematological
toxicity was nausea and vomiting (21/30 patients, WHO grade ≥ 2). Serious nephrotoxicity was observed early in the renal cancer
study and, later, also in the melanoma study. Hyperhydration did not prevent the nephrotoxicity, and the studies were stopped
after 6 renal cancer patients and 24 malignant melanoma patients had been included. Zeniplatin gave objective responses in
3 of the 21 evaluable malignant melanoma patients [2 complete responses (CRs) in patients with lymph-node metastases lasted
5 and 14 months, respectively; 1 partial response (PR) in a patient with lymph-node and liver metastases lasted 6 months].
In the renal cancer study, only four patients were evaluable for response and none responded. The results show that zeniplatin
has some activity (14%) in patients with advanced malignant melanoma, but no conclusion can be drawn regarding the activity
of zeniplatin in renal cancer as the number of patients was too low. The main toxicities were leukopenia and nausea and vomiting.
Unexpected and serious nephrotoxicity was observed, and for this reason the studies were terminated before the planned number
of patients had been included. A possible explanation for the nephrotoxicity may be drug interactions, but no firm conclusion
can yet be drawn.
Received: 16 March 1996 / Accepted: 25 March 1997 相似文献
63.
Radiation-Induced Apoptosis: The Ceramide-SAPK Signaling Pathway and Clinical Aspects 总被引:2,自引:0,他引:2
Marcel Verheij Wim J. van Blitterswijk Harry Bartelink 《Acta oncologica (Stockholm, Sweden)》1998,37(6):575-581
Apoptosis, or programmed cell death is an important regulatory mechanism that is involved in a variety of homeostatic processes. Decreased cellular sensitivity or inappropriate responses to apoptotic stimuli may be important factors in tumorigenesis and resistance to anticancer treatments. It is generally accepted that all mammalian cells constitutively express the biochemical machinery to execute apoptosis. It is, however, not clear which signal transduction pathways are involved, or to which extent various stimuli activate independent or partially overlapping pathways. In this paper we discuss the involvement of a ceramide-mediated stress-activated protein kinase (SAPK) signaling cascade in radiation-induced apoptosis. Furthermore, examples are presented of pharmacological intervention in specific signal transduction pathways that lead to modulation of the apoptotic response. Finally, data are presented to illustrate the potential clinical relevance of apoptosis. 相似文献
64.
65.
Adrienne H Brouwers Peter F A Mulders Pieter H M de Mulder Wim J M van den Broek Wilhelmina C A M Buijs Carola Mala Frank B M Joosten Egbert Oosterwijk Otto C Boerman Frans H M Corstens Wim J G Oyen 《Journal of clinical oncology》2005,23(27):6540-6548
PURPOSE: A previous activity dose-escalation study using 131I-labeled chimeric monoclonal antibody cG250 in patients with progressive metastatic renal cell carcinoma (RCC) resulted in occasional therapeutic responses. The present study was designed to determine the safety and therapeutic efficacy of two sequential high-dose treatments with 131I-cG250. PATIENTS AND METHODS: Patients (n = 29) with progressive metastatic RCC received a low dose of (131)I-cG250 for assessment of preferential targeting of metastatic lesions, followed by the first radioimmunotherapy (RIT) with 2220 MBq/m2 131I-cG250 (n = 27) 1 week later. If no grade 4 hematologic toxicity was observed, a second low-dose 131I-cG250 (n = 20) was given 3 months later. When blood clearance was not accelerated, a second RIT of 131I-cG250 was administered at an activity-dose of 1110 MBq/m2 (n = 3) or 1665 MBq/m2 (n = 16). Patients were monitored weekly for toxicity, and tumor size was evaluated by computed tomography once every 3 months intervals. RESULTS: The maximum-tolerated dose (MTD) of the second RIT was 1,665 MBq/m2 because of dose-limiting hematological toxicity. Based on an intention-to-treat analysis, after two RIT treatments, the disease stabilized in five of 29 patients, whereas it remained progressive in 14 of 29 patients. Two patients received no RIT, and eight of 29 received only one 131I-cG250 RIT because of grade 4 hematologic toxicity, formation of human antichimeric antibodies, or disease progression. CONCLUSION: In patients with progressive end-stage RCC, the MTD of the second treatment was 75% of the MTD of the first RIT. In the majority of patients, two cycles of 131I-cG250 could be safely administered without severe toxicity. No objective responses were observed, but occasionally two RIT doses resulted in stabilization of previously progressive disease. 相似文献
66.
Mohammad Obaidul Hoque Ozlem Topaloglu Shahnaz Begum Rui Henrique Eli Rosenbaum Wim Van Criekinge William H Westra David Sidransky 《Journal of clinical oncology》2005,23(27):6569-6575
PURPOSE: Aberrant promoter hypermethylation of several known or putative tumor suppressor genes occurs frequently during the pathogenesis of prostate cancers and is a promising marker for cancer detection. We sought to develop a test for prostate cancer based on a quantitative methylation-specific polymerase chain reaction (QMSP) of multiple genes in urine sediment DNA. PATIENTS AND METHODS: We tested urine sediment DNA for aberrant methylation of nine gene promoters (p16INK4a, p14(ARF), MGMT, GSTP1, RARbeta2, CDH1 [E-cadherin], TIMP3, Rassf1A, and APC) from 52 patients with prostate cancer and 21 matched primary tumors by quantitative fluorogenic real-time polymerase chain reaction. We also analyzed urine sediments from 91 age-matched individuals without any history of genitourinary malignancy as controls. RESULTS: Promoter hypermethylation of at least one of the genes studied was detected in urine samples from all 52 prostate cancer patients. Urine samples from the 91 controls without evidence of genitourinary cancer revealed no methylation of the p16, ARF, MGMT, and GSTP1 gene promoters, whereas methylation of RARbeta2, TIMP3, CDH1, Rassf1A, and APC was detected at low levels. CONCLUSION: Overall, methylation found in urine samples matched the methylation status in the primary tumor. A combination of only four genes (p16, ARF, MGMT, and GSTP1) would theoretically allow us to detect 87% of prostate cancers with 100% specificity. Our data support further development of the noninvasive QMSP assay in urine DNA for early detection and surveillance of prostate cancer. 相似文献
67.
Immunogenicity of meningococcal PorA formulations encapsulated in biodegradable microspheres. 总被引:1,自引:0,他引:1
Carmen Arigita Joost van den Berg Karin Wensink Mies van Steenbergen Wim E Hennink Daan J A Crommelin Gideon F A Kersten Wim Jiskoot 《European journal of pharmaceutical sciences》2004,21(2-3):131-141
The purpose of our study was to investigate the possibility to microencapsulate liposomes and meningococcal outer membrane vesicles (OMV), both containing neisserial pore protein A (PorA), in biodegradable dextran- and mannan-based microspheres and to study the immunogenicity of the encapsulated PorA formulations. PorA-liposomes and OMV were encapsulated in dextran- or mannan-based microspheres by using an aqueous two-phase system consisting of a polyethylene glycol solution and a methacrylated dextran or mannan solution. The formulations were characterized for size distribution, PorA structure and antigen recovery after release. Calcein-containing model liposomes were used to establish the encapsulation efficiency and release profiles from both types of microspheres. The immunogenicity of the PorA-containing formulations was determined in mice after subcutaneous immunization. Liposomes were encapsulated in dextran and mannan microspheres with a high efficiency (70-90%). Calcein liposomes, after a 5-day lag period, exhibited apparent zero-order release kinetics from both types of microspheres between Days 5 and 10 of incubation in vitro. The total release was 80 and 100% from mannan and dextran microspheres, respectively. The trimeric PorA conformation was preserved in the released liposomes and OMV and the antigen was partly recovered. The immunogenicity of PorA-liposomes and OMV encapsulated in dextran or mannan microspheres was preserved. In conclusion, PorA-liposomes and OMV could be encapsulated in dextran- and mannan-based microspheres with high efficiency. The immunogenicity of encapsulated antigen was preserved. 相似文献
68.
Gerhard J Nohynek Julie A Skare Wim J A Meuling David W Hein Albert Th H J De Bie Herve Toutain 《Food and chemical toxicology》2004,42(11):1885-1891
In the organism of mammals, important detoxification pathways of arylamines are catalysed by N-acetyltransferase 2 (NAT2). A recent case-control epidemiology study suggested that human NAT2 slow acetylators exposed to oxidative hair dyes may be at greater risk to develop bladder cancer. We therefore profiled urinary [(14)C]-metabolites and NAT2 genotype in eight human subjects following treatment with a dark-shade oxidative hair dye containing [(14)C]-para-phenylenediamine (PPD). Genotyping identified three subjects as slow, and five subjects as intermediate NAT2 acetylators. Within 24 h after treatment, the study subjects excreted a mean total of 0.43+/-0.24% of the applied [(14)C] in the urine, where five different metabolites were found. The major urinary metabolites were concluded to be N-mono-acetylated and N,N'-diacetylated PPD. They were present in all urine samples and amounted to 80-95% of the total urinary [(14)C]. Another metabolite, possibly a glucuronic acid conjugate, was found in 6/8 urine samples at 5-13% of the total urinary [(14)C]. All metabolites appeared to be related to PPD, no evidence of the presence of high-molecular weight dye-intermediates or corresponding metabolites was found. The metabolite profile in the study subjects showed no significant differences between the NAT2 intermediate and NAT2 slow acetylator subgroups. Urine of NAT2 slow acetylators contained N-mono-acetylated-PPD at 42.2+/-10.2% and N,N'-di-acetylated-PPD at 54.1+/-7.6% of total urinary radioactivity, while the corresponding values of intermediate acetylators were 46.0+/-8.9% and 45.7+/-9.9%, respectively. Overall, our results suggest that the human acetylation rate of PPD after topical application is independent of the NAT2 genotype status, most likely due to metabolism by epidermal NAT1 prior to systemic absorption. 相似文献
69.
70.